Erratum: Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: A case report and discussion of the relevant literature (Annals of Hematology (2004) vol. 83 (661-665) 10.1007/s00277-004-0895-2)

Annals of Hematology

Volumn 84, Issue 6, 2005, Pages 411-415

  Hefer, David ^a   Jaloudi, Mohammed ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL; AGED; BLOOD; CASE REPORT; HUMAN; MALE; REVIEW; THROMBOEMBOLISM;

IMMUNOGLOBULIN;

AGED; AGED, 80 AND OVER; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; THROMBOEMBOLISM;

EID: 20444471583     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1024-6     Document Type: Erratum

References (46)

1. Walsh PM (2003) Physicians' desk reference, 57th edn. Thompson, Montvale
2. Ratko TA, Burnett DA, Foulke GE et al (1995) Recommendations for off label use of intravenously administered immunoglobulin preparations. JAMA 273:1865-1870 10.1001/jama.273.23.1865
3. Stangel M, Hartung HP, Marx P et al (1997) Review side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 20(5):385-393 1:CAS:528:DyaK2sXmslWrtr0%3D
4. Misbah SA, Chapel HM (1993) Adverse effects of intravenous immunoglobulin. Drug Saf 9(4):254-262 1:STN:280:ByuD1c3ps10%3D
5. Ryan ME, Webster ML, Statler JD (1996) Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr (Phila) 35(1):23-31
6. Hayakawa F, Imada K, Towatari M et al (2002) Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 118:1187-1189 10.1046/j.1365-2141.2002.03741.x
7. Stangel M, Hartung HP, Marx P et al (1998) Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 153:203-214 10.1016/S0022-510X(97)00292-X
8. Martin TD (1999) Safety and tolerability of intravenous immunoglobulins. Electroencephalogr Clin Neurophysiol Suppl 50:514-520 1:STN:280:DC%2BD3c7lsVSqsA%3D%3D
9. Nydegger UE, Sturzenegger M (1999) Adverse effects of intravenous immunoglobulin therapy. Drug Saf 3:171-185
10. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747-755 10.1056/NEJMra993360
11. Otsuki T, Funakawa T, Sugihara T et al (1997) Multiple cerebral infarctions in a patient with refractory idiopathic thrombocytopenic purpura. J Intern Med 241:249-252 10.1046/j.1365-2796.1997.72899000.x
12. Fuchi T, Kondo T, Sase K et al (1999) Primary percutaneous transluminal coronary angioplasty performed for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. Jpn Circ J 63:133-136 10.1253/jcj.63.133
13. Koch CA, Archer TP, Kraut EH (1997) Myocardial ischemia in a patient with chronic refractory idiopathic thrombocytopenic purpura (letter). Arch Intern Med 157:2668 10.1001/archinte.157.22.2668b
14. Fruchter O, Blich M, Jacob G (2002) Fatal acute myocardial infarction during severe thrombocytopenia in a patient with idiopathic thrombocytopenic purpura. Am J Med Sci 323(5):279-280 10.1097/ 00000441-200205000-00010
15. Haplea SS, Farrar JT, Gibson GA et al (1997) Thromboembolic events associated with intravenous immunoglobulin therapy (abstract). Neurology 48:A54
16. Strasser-Fuchs S, Fazekas F, Deisenhammer F et al (2000) The Austrian Immunoglobulin in MS (AIMS) study: Final analysis. Mult Scler 6[Suppl 2]:S9-S13 1:CAS:528:DC%2BD3cXovVersLk%3D
17. Poehlau D et al (2000) Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins - interim results on drug safety of an ongoing study. Mult Scler 6[Suppl 2]:S21-S23 2 S21-S23 1:CAS:528:DC%2BD3cXovVersb4%3D
18. Leger JM, Chassande B, Musset L et al (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy - a double-blind, placebo-controlled study. Brain 124:145-153 10.1093/brain/124.1.145
19. Wolfe GI, Barohn RJ, Foster BM et al (2002) Randomized, controlled trial of intravenous immunoglobulin in mysthenia gravis. Muscle Nerve 26:549-552 10.1002/mus.10224
20. Mendell JR, Barohn RJ, Freimer ML et al (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445-449 1:CAS:528:DC%2BD3MXhvFelsbw%3D
21. Jurlander J, Hartmann Geisler C, Hansen MM (1994) Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 53:114-118 1:STN:280:ByuA2svltVI%3D
22. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia - a randomized, controlled clinical trial. N Engl J Med 319:902-907 2901668
23. Sherer Y, Levy Y, Langevitz P et al (2001) Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 62:133-137 10.1159/000056085
24. Woodruff RK, Grigg AP, Firkin FC, Smith IL (1986) Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients (letter). Lancet 2:217-218 10.1016/ S0140-6736(86)92511-0
25. Reinhart WH, Berchtold PE (1992) Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339:662-664 10.1016/ 0140-6736(92)90806-E
26. Dalakas MC (1994) High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 44:223-226 1:STN:280:ByuC2c3ovFE%3D
27. Oh KT, Boldt HC, Danis RP (1997) Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 124(3):416-418 1:STN:280:DyaK1c7gt1Crug%3D%3D
28. Harkness KA, Goulding P (2000) Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye 14(Pt 4):662-663 11040920
29. Turner B, Wills AJ (2000) Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 68:790-791 10.1136/jnnp.68.6.790
30. Mathy I, Gille M, Van Raemdonck F et al (1998) Neurological complications of intravenous immunoglobulin (IVIg) therapy: An illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg 98:347-351 1:STN:280:DyaK1M7itFGkug%3D%3D
31. Wolberg AS, Kon RH, Monroe DM et al (2000) Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 65:30-34 10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.3.CO;2-A
32. Fisman DN, Smilovitch M (1997) Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 13(8):775-777 1:STN:280:ByiH3s%2Fntlw%3D
33. Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75:83-85 1:STN:280:DC%2BD3c%2FpsVCmug%3D%3D
34. Emerson GG, Herndon CN, Sreih AG (2002) Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 22(12):1638-1641 10.1592/phco.22.17.1638.34125
35. Silbert PL, Knezevic WV, Bridge DT (1992) Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 42:257-258 1:STN:280:By2C3s7ivFw%3D
36. Ropper AH, Adelman L (1992) Early Guillain-Barré syndrome without inflammation. Arch Neurol 49:979-981 1:STN:280:By2A1M3gslQ%3D
37. Steg RE, Lefkowitz DM (1994) Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 44:1180-1181 1:STN:280:ByuB28fntVc%3D
38. Brannagan TH III, Nagle KJ, Lange DJ, Rowland LP (1996) Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47:674-677 8797463
39. Rosenbaum JT (1997) Myocardial infarction as a complication of immunoglobulin therapy (letter). Arthritis Rheum 40(9):1732-1733 1:STN:280:ByiH28vitFM%3D
40. Paolini R, Fabris F, Cella G (2000) Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP) (letter). Am J Hematol 65(2):177-178 10.1002/1096-8652(200010)65:2<177::AID-AJH17>3.0.CO;2-K
41. Elkayam O, Paran D, Milo R et al (2000) Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders: Astudy of four cases. Ann Rheum Dis 59:77-80 10.1136/ard.59.1.77
42. Steinberger B, Coleman TA (2001) Multiple complications of IVIg therapy in a patient with Guillain-Barré syndrome. Am J Hematol 67(1):59 10.1002/ajh.1080
43. Alliot C, Rapin JP, Besson M et al (2001) Pulmonary embolism after intravenous immunoglobulin. J R Soc Med 94:187-188 1:STN:280:DC%2BD3M3kvFSmsA%3D%3D
44. Byrne NP, Henry JC, Herrmann DN et al (2002) Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy. Neurology 59:458-461 1:STN:280:DC%2BD38visVWnsQ%3D%3D
45. Crouch ED, Watson LE (2002) Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura: A case report and literature review. Angiology 53:113-117 11863304
46. Evangelou N, Littlewood T, Anslow P et al (2003) Transverse sinus thrombosis and IVIg treatment: A case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 56:308-309 10.1136/jcp.56.4.308